A2RL
On Saturday, April 27th, Abu Dhabi will host a groundbreaking event, welcoming 10,000 spectators to witness the inaugural ASPIRE Abu Dhabi Autonomous Racing League (A2RL) at the iconic Yas Marina Circuit. This brand-new autonomous racing competition marks a significant milestone in motorsport history, billed as the largest league of its kind globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423980323/en/
Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 27 (Photo: AETOSWire)
Eight teams will compete: Code19 Racing (one of the first independent autonomous racing entity from the USA), Constructor University (based in Germany and Switzerland), Fly Eagle (representing Beijing Institute of Technology from China and Khalifa University from the UAE), HUMDA Lab (a member of the Széchenyi István University Group from Hungary), KINETIZ (a collaboration between Singapore Nanyang Technological University and Kintsugi based in the UAE), PoliMOVE (representing Politecnico di Milano from Italy), UNIMORE (also from Italy - University of Modena and Reggio Emilia), and Technical University of Munich - TUM (from Germany), vying for a substantial prize purse of US$ 2.25 million.
The participating teams of coders and engineers will each have exclusive access to identical Dallara Super Formula SF23 cars, made possible through a partnership with Japan Race Promotions. These cars will be autonomized with autonomous racing stacks developed and integrated by the Technology Innovation Institute (TII). The sole variable lies in how each team utilizes their coding skills, AI algorithms, and machine learning software development expertise to teach their cars how to drive. Currently recognized as the fastest open-wheel race car in the world after Formula One, these cars can reach speeds of up to 300 km/h.
For the first time, the race format is poised to feature four autonomous cars driving on the racetrack simultaneously – a feat never before attempted. In a series of pre-qualifying races, the finale will showcase the top performers from the Lap Test and Speed Test, advancing to a final Overtaking Challenge to determine the ultimate winner. Additionally, an AI vs Human car race will unfold, with the Technology Innovation Institute (TII) embracing the electrifying challenge of pitting their autonomous car against former F1 driver – Daniil Kvyat. TII will aim to get as close as possible to the human lap time and will also demonstrate the autonomous car’s ability to drive without GPS assistance.
H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council - ASPIRE’s parent entity, and Advisor to the UAE President on Strategic Research and Advanced Technology Affairs, said: "In pushing the boundaries of technology under extreme conditions, we uncover new frontiers in science. This reimagined racing paradigm harnesses the pinnacle of coding skills, AI algorithms, and software development prowess — the very skill sets of the future. By leveraging these capabilities, we pave a path at the forefront of research and development, propelling Abu Dhabi to become a pivotal global hub for innovation."
ADNOC has come on board as title sponsor, providing crucial support, underscoring the widespread enthusiasm for advancing autonomous racing technology. H.E. Dr. Sultan Al Jaber, Minister of Industry and Advanced Technology, and Group MD & CEO of ADNOC, added: "As we navigate the path to UAE's industrial future, our commitment to in-country value and technological advancement stands unwavering. A2RL epitomizes our dedication to integrating cutting-edge technology including AI, driving competitiveness and economic growth across sectors. For decades, ADNOC has invested in the latest technology and innovation – from the control room, to the board room - to deliver the modern energy that powers our lives."
Organizer of A2RL, ASPIRE CEO Stephane Timpano said: "A2RL is more than just a race — it's a platform for testing and optimizing autonomous vehicle technologies, enhancing safety and reliability on public roads. With the support of local and international partners, we're bringing the mobility future - closer." The inaugural race has attracted a diverse array of sponsors, each contributing their expertise and resources to ensure the success of the development of the cutting-edge autonomized cars. Leading partners, such as Du, DMT, AWS, and Mubadala, have played pivotal roles in shaping the event’s trajectory, with media partners such Motorsports, Inc. Arabia, FastCompany Middle East, and What’s On, amplifying A2RL’s visibility.
Technical partners, including Dallara, Danisi Engineering, Meccanica 42, Kistler, Seyond, Eventagrate, Live in Five, Focal Point VR and Vislink, have lent their specialized knowledge to elevate the event's innovation and performance standards.
An exclusive Fan Zone promises an elevated experience for families, motorsport fans, and tech enthusiasts alike. With tailored activities, guests can immerse themselves in cutting-edge tech and gaming, including a captivating VR zone and the AI museum – Raceum. From 16:00 (GST) on April 27, young students from the A2RL STEM Competition will showcase their coding skills on 1:8 scale autonomous racing cars, with 18 schools competing to add excitement. The night concludes at 23:00 (GST), with activities including a podium ceremony for the winners, fireworks, a drone show, and an after-show concert with DJ Andre Soueid.
For those unable to attend in person, the excitement of Race Day will be accessible through various live streaming channels, including A2RL’s official YouTube and Twitch channels, motorsport.tv and the A2RL app. Interested parties are invited to visit the A2RL website and monitor social media channels for updates regarding the program schedule and details on viewing the race in their respective regions.
The inaugural A2RL event is part of Abu Dhabi Mobility Week, running from April 24 to May 1.
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423980323/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 13:30:00 CEST | Press release
Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom